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Background
The viral load test provides important information that is
used in conjunction with the CD4 cell count: to monitor
the status of HIV disease, to guide recommendations for
therapy, and to predict the future course of HIV, decreases
the complications of HIV disease and prolongs life. As per
National AIDS Control Organization (NACO) Guidelines
HIV-1 infected patients are treated with either one of the
primary line regimen as follows SLN (Stavudine + Lami-
vudine + Nevirapine) Group A, ZLN (Zido-vudine + Lam-
ivudine + Nevirapine) Group B, SLE (Stavudine +
Lamivudine + Efavirenz) Group C, ZLE (Zidovudine +
Lamivudine + Efavirenz) Group D.
Materials and methods
A total of 214 HIV-1 infected patients attending the virol-
ogy OPD of KEM Hospital who were on Primary line ART
were recruited for the study. All these patients were evalu-
ated for their CD4 Count by using BD Flowcytomter and
their plasma RNA Viral Load by Taqman Probes using
Roche RT-PCR machine.
Results
In 214 HIV-1 infected Group A (SLN) patients showed
mean CD4 count 330.5 that was 278.6 six months ago.
Mean CD4 count of Group B (ZLN) was 306.6 six months
ago and now decreased to 256.3. Mean CD4 count of
Group C (SLE) was 244 six months ago and changed to
181.5. Group D (ZLE) patients showed slight decrease in
the mean CD4 count. A total of 42% patients had Gastro
intestinal discomfort and Insomnia. 7 patients on ZLN
regimen, 2 patients on SLE regimen had viral load more
than 1000 copies/ml. No patients from ZLE regimen had
viral load above 1000 copies/ml. Widely used SLN regi-
men patients had viral load ranging from 1042 copies/ml
to 31,13,018 copies/ml. Out of 214 HIV-1 infected
patients, 30 patients showed a range of viral load copies
from 57 to 31,13018. 17 out of 30 patients were on SLN
(Group A). 50% among them showed viral load more
than 9000 copies/ml. 9 patients out of 30 were on Group
B (ZLN). More than 50% among these had viral load
above 15,000 copies/ml. Only 2 patients of each Group C
(SLE) & Group D (ZLE) had increased viral load. Recom-
mended ART regimen is expected to decrease viral load
and increase CD4 count.
Conclusion
Our Study confirms that The HIV cross clade variants is
produced depending on the antiretroviral drug and the
host genetic factors.
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